Introduction: An Old Drug, A Fresh Look

Most people know candesartan as a blood pressure medication. It belongs to a class of drugs called angiotensin receptor blockers, or ARBs, and it has been on pharmacy shelves for decades. What is less well known is that candesartan has quietly built a reputation as a migraine preventive too.

For years the evidence was scattered across a handful of small trials, which is part of why guidelines in different countries disagree on where ARBs belong. A new systematic review and meta-analysis published in May 2026 in the journal Cephalalgia pulled that evidence together and the picture got a lot clearer. The headline: candesartan and related ARBs do reduce migraine days, and for the simplest outcome the certainty of evidence is now rated as high.

What Are ARBs?

ARBs block a receptor for angiotensin II, a hormone that tightens blood vessels and raises blood pressure. By blocking that receptor, ARBs relax blood vessels and lower pressure. Candesartan and telmisartan are two common examples, and both showed up in the migraine research.

The renin-angiotensin system that these drugs act on is not just about blood pressure. It is also active in the brain, where it influences blood flow, inflammation, oxidative stress, and how nerves respond to stress. That overlap is the reason researchers started testing a blood pressure drug for headaches in the first place.

How ARBs May Work in Migraine

The honest answer is that nobody has nailed down a single mechanism. Migraine is complex, and ARBs touch several systems that are thought to play a role. Here are the leading ideas.

Importantly, candesartan lowers migraine frequency at doses that often have only a modest effect on blood pressure in people who start with normal readings, which suggests the migraine benefit is not just a side effect of lower blood pressure.

The New Meta-Analysis: What the Research Shows

A team from the Norwegian Centre for Headache Research searched the major medical databases through September 2025 for controlled trials comparing an ARB to placebo or to another preventive in people with episodic or chronic migraine. They combined the results using standard meta-analysis methods and graded the quality of the evidence.

Summary of the Pooled Findings

This table summarizes the main results of the 2026 meta-analysis of ARBs for migraine prevention, including effect sizes, confidence intervals, and how confident the authors were in each result.

In plain terms, people on an ARB were roughly two and a half times more likely to be "responders," meaning they cut their migraine days by half or more. The reduction in raw migraine days looks modest at about one day a month, but for someone with frequent attacks that can be meaningful, and the responder odds tell a more encouraging story.

Putting the Numbers in Context

One day fewer per month is on par with what several established oral preventives deliver in trials, so candesartan is not an outlier in either direction. The real takeaway is that the evidence has matured. The authors argue these findings support reconsidering where ARBs, candesartan in particular, sit in international migraine guidelines.

Safety Profile and What to Watch

One of candesartan's selling points is that it is generally well tolerated. ARBs have been used by millions of people for blood pressure, so the side effect profile is well mapped. That said, it is still a real medication with real precautions.

People with low blood pressure, kidney disease, or certain electrolyte problems need extra caution, and candesartan should not be combined casually with other drugs that affect the same system, such as ACE inhibitors. Your doctor will weigh all of this against your other health conditions.

Dosing and Practical Use

In the migraine trials, candesartan was typically used at 16 mg once daily, the same kind of dose used for blood pressure. Telmisartan was studied at 80 mg daily. As with most migraine preventives, the benefit builds over weeks rather than days, so it is not something you judge after a single dose.

How Candesartan Compares to Other Preventives

Migraine prevention has a crowded shelf: beta-blockers like propranolol, topiramate, amitriptyline, and the newer CGRP-targeted drugs. Candesartan does not replace these, but it fills a useful gap.

Earlier head-to-head research found candesartan worked about as well as propranolol, a long-standing first-line preventive. For patients who cannot take beta-blockers, who have not done well on other options, or who would benefit from treating blood pressure at the same time, candesartan is a reasonable thing to discuss.

"The evidence has finally caught up with what some headache specialists suspected for years: a familiar blood pressure pill earns a real place in the migraine prevention toolkit." - Cerebral Torque

Who Might Be a Good Candidate

Talking to Your Doctor

Candesartan is prescription only, so this is a shared decision with your clinician rather than something to start on your own. A few things that help the conversation go smoothly:

Conclusions

The 2026 meta-analysis does not claim candesartan is a miracle cure, and neither should we. What it does is move ARBs from "promising but uncertain" toward "supported by solid evidence," with a high-certainty grade for the reduction in headache days and a meaningful boost in the odds of cutting migraine days in half.

For a cheap, familiar, once-a-day pill, that is a genuinely useful addition to the migraine prevention conversation. If your current plan is not cutting it, candesartan is worth asking about.